Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.
Journal Article (Journal Article;Review)
Hematopoietic stem cell transplantation (HCT) has been increasingly used for patients with inherited metabolic disorders (IMD). Immune mediated cytopenias (IMCs) after HCT, manifesting as hemolytic anemia, thrombocytopenia, and/or neutropenia, are recognized as a significant complication in this patient population, yet our understanding of the incidence, risk factors, and pathophysiology is currently limited. Review of the published literature demonstrates a higher incidence in younger patients who undergo HCT for a nonmalignant disease indication. However, a few reports suggest that the incidence is even higher among those with IMD (incidence ranging from 10 to 56%). This review summarizes the literature, provides an approach to better understanding of the possible etiology of IMCs, and proposes a diagnostic and management plan for patients with IMD who develop single or multi-lineage cytopenias after HCT.
- Published version (via Digital Object Identifier)
- Pubmed Central version
- Open Access Copy from Duke
- Link to Item
- Gupta, AO; Jan Boelens, J; Ebens, CL; Kurtzberg, J; Lund, TC; Smith, AR; Wagner, JE; Wynn, R; Blazar, BR; Orchard, PJ
- June 2021
Volume / Issue
- 56 / 6
Start / End Page
- 1238 - 1247
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)